GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Neisseria Meningitidis Burden of Disease Study

Completed

Conditions: Neisseria Meningitidis
Streptococcus Pneumoniae
Haemophilus Influenzae

Interventions: Other: Data collection
Other: CSF samples testing

First Posted Date: 2012-11-21

Last Posted Date: 2015-11-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 521

Registration Number: NCT01730391

Locations: 🇻🇳
GSK Investigational Site, Hanoi, Vietnam

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Prepandrix™
Biological: Fluarix™

First Posted Date: 2012-11-21

Last Posted Date: 2018-09-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 131

Registration Number: NCT01730378

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: BENLYSTA
Other: SLE treatment

First Posted Date: 2012-11-20

Last Posted Date: 2025-05-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3138

Registration Number: NCT01729455

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: FF 400 mcg
Drug: UMEC 500 mcg
Drug: FF/UMEC 400/500 mcg

First Posted Date: 2012-11-14

Last Posted Date: 2017-06-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT01725685

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Phase 1

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin, 1000 mg extended release tablet
Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers
Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers
Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers
Drug: Metformin, 500 mg extended release tablet
Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers
Drug: Glimepiride, 2 mg immediate release tablet
Drug: Glimepiride, 1 mg immediate release tablet